13F Holdings
中文EN

KLRS Kalaris Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1754068 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY21.8%
TTM EPS YoY90.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-97.2%
ROA-51.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets46.7%
Debt / equity0.00x
Current ratio10.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$30.75M$45.04M$133.07M$118.87M$120.73M
SG&A expense$15.40M$6.69M$48.26M$52.33M$49.08M
Operating income-$46.15M-$51.73M-$199.90M-$171.20M-$169.82M
Interest expense$1.44M$2.70M———
Pretax income-$43.44M-$69.17M-$190.54M-$168.97M-$170.96M
Income tax$0$0-$126,000-$265,000$1.01M
Net income-$43.44M-$69.17M-$190.42M-$168.71M-$171.96M
EBITDA-$46.14M—-$199.50M-$170.48M-$169.63M
EPS (basic)-2.85-51.77-42.09-2.20-2.74
EPS (diluted)-2.85-51.77-42.09-2.20-2.74
Weighted avg. shares (diluted)15.27M1.34M4.52M76.65M62.78M
Balance sheet
Cash & equivalents$98.05M$1.64M$90.12M$106.09M$201.66M
Short-term investments$19.93M$0$93.82M$127.70M$46.46M
Current assets$118.81M$2.61M$187.63M$243.05M$253.35M
PP&E, net———$930,000$1.55M
Total assets$121.74M$6.16M$190.80M$277.08M$286.59M
Current liabilities$9.71M$24.70M$28.37M$24.34M$37.85M
Total liabilities$42.92M$56.78M$45.02M$52.56M$61.33M
Shareholders' equity$78.81M-$96.62M-$45.02M$224.52M$225.27M
Shares outstanding22.90M1.36M4.96M93.09M63.57M
Cash flow statement
Operating cash flow-$38.37M-$20.67M-$124.45M-$142.05M-$106.32M
Capital expenditure$200,000———$26,000
Free cash flow-$38.57M———-$106.34M
Investing cash flow-$19.72M$95.00M$37.98M-$80.48M$185.98M
Financing cash flow$155.01M$19.14M$70.50M$126.96M$232,000
Depreciation & amortization$13,000—$398,000$723,000$189,000
Stock-based compensation$1.94M$895,000$40.78M$41.31M$43.98M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.